GAM Holding’s Nektar Therapeutics NKTR Stock Holding History

GAM Holding’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-3,427	Closed	-$1.03M	–	335
2021 Q1	$1.03M	Buy	+3,427	New	+$1.07M	0.05%	234
2020 Q4	–	Sell	-4,833	Closed	-$1.2M	–	312
2020 Q3	$1.2M	Hold	4,833	–	–	0.07%	235
2020 Q2	$1.68M	Buy	4,833 +1,173	+32%	+$366K	0.1%	211
2020 Q1	$980K	Buy	3,660 +847	+30%	+$262K	0.07%	231
2019 Q4	$911K	Hold	2,813	–	–	0.04%	286
2019 Q3	$769K	Hold	2,813	–	–	0.03%	461
2019 Q2	$1.5M	Hold	2,813	–	–	0.06%	351
2019 Q1	$1.42M	Hold	2,813	–	–	0.06%	328
2018 Q4	$1.39M	Sell	2,813 -340	-11%	-$205K	0.07%	281
2018 Q3	$2.88M	Buy	3,153 +706	+29%	+$603K	0.1%	216
2018 Q2	$1.79M	Buy	+2,447	New	+$2.82M	0.06%	306
2013 Q4	–	Sell	-1,540	Closed	-$241K	–	995
2013 Q3	$241K	Buy	+1,540	New	+$285K	﹤0.01%	915

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

GAM Holding's NKTR Position: Q2 2021 in Review

GAM Holding sold out of Nektar Therapeutics (NKTR) in Q2 2021, closing a stake of 3,427 shares — an estimated $1.03M sold.

GAM Holding first reported a position in NKTR in Q3 2013 and held it in 12 quarters. The position peaked at $2.88M in Q3 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2021.

GAM Holding reported no remaining Nektar Therapeutics position as of Q2 2021 after selling out during the quarter.
GAM Holding sold 3,427 Nektar Therapeutics shares in Q2 2021, an estimated $1.03M.
GAM Holding first reported a position in Nektar Therapeutics in Q3 2013 and held it in 12 quarters.
GAM Holding's Nektar Therapeutics position peaked at $2.88M in Q3 2018.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2021.

Based on GAM Holding's 13F filing for Q2 2021, filed 9 Aug 2021.